RSS

haemophilia B

Pfizer and Spark Therapeutics have announced that the Phase III programme for the investigational haemophilia B gene therapy is to be initiated by Pfizer. Read more

News

A capsule has been developed that can treat people affected by the hereditary bleeding disorder haemophilia. Read more

News

The University College London Technology Fund has announced an investment of up to £1 million for the development of gene therapies Read more

News